Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

The companies plan to test the treatment's efficacy in preclinical models of squamous cell lung carcinoma early next year.

The firm said treatment with the autologous immunotherapy demonstrated increased overall survival compared to placebo in a Phase II study.

Project GENIE will use the funding to build an AI-based tool to perform multilingual clinical data translation and expand global access to the registry.

The firm received guidance from the FDA during a recent type B meeting on the study's inclusion criteria, design, and statistical parameters.

The agency is proposing drugmakers use shorter nonrodent studies and other sources of evidence when developing monoclonal antibodies for non-cancer settings.

The study will test the therapy in lung, colorectal, and head and neck cancer patients with B7H3 and PTK7 mutations.

The company is evaluating EN-374 in patients with X-linked chronic granulomatous disease as part of a Phase I/II trial.

NEW YORK – BiPER Therapeutics on Tuesday said it has raised €1 million ($1.16 million) to advance its lead candidate, the BiP inhibitor BPR001-615, into clinical trials for gastrointestinal cancers ...

Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk will collaborate with PRECISE to analyze whole-genome and other data on 100,000 Singaporeans.

The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.

The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel ...